Current Report Filing (8-k)
May 02 2022 - 4:02PM
Edgar (US Regulatory)
0000895051
false
0000895051
2022-05-02
2022-05-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 2, 2022
CASI PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in
its Charter)
delaware
(State or other
jurisdiction of
incorporation or organization) |
0-20713
(Commission File Number)
|
58-1959440
(IRS Employer
Identification
No.) |
9620 Medical Center Drive, Suite 300
Rockville, Maryland
(Address of principal executive offices)
20850
(Zip Code)
(240) 864-2600
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of exchange on which registered |
Common Stock |
|
CASI |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On
May 2, 2022, CASI Pharmaceuticals, Inc. (the “Company”) received a notice of termination of the MARQIBO® license agreement from Acrotech Biopharma
LLC (“Acrotech”) related to its withdrawal of its product MARQIBO® from the US market.
The
parties have mutually agreed to terminate the original license agreement dated September 17, 2014 between Talon Therapeutics, Inc.
(“Talon”) and the Company. Acrotech assumed the license agreement from Talon. Due to the evolving standard of care
environment, the rare and niche indication for MARQIBO® in the licensed territory, and the Company’s commitment to
prioritize resources, MARQIBO® has been a deprioritized Company asset.
| Item 9.01 | Financial Statements and Exhibits. |
|
Exhibit |
|
|
|
Number |
|
Description |
|
|
|
|
|
104 |
|
Inline XBRL for the cover page of this Current Report on Form 8-K |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CASI PHARMACEUTICALS, INC. |
|
(Registrant) |
|
|
|
|
|
/s/ Alexander Zukiwski |
|
|
CMO and EVP |
|
Date: May 2, 2022
CASI Pharmaceuticals (NASDAQ:CASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
CASI Pharmaceuticals (NASDAQ:CASI)
Historical Stock Chart
From Sep 2023 to Sep 2024